Integra LifeSciences (NASDAQ:IART) Stock Rating Raised to "Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Integra LifeSciences to “Buy” from “Hold,” though broader analyst sentiment remains cautious, with a consensus “Reduce” rating and an average price target of $16.12.
• Integra reported quarterly EPS of $0.59, exceeding the $0.56 consensus estimate, while revenue of $411.18 million fell slightly short of expectations.
• The stock opened at $12.75, near the lower end of its 12-month range of $8.70 to $20.49. Institutional investors own approximately 84.78% of the company’s shares.

Integra LifeSciences (NASDAQ:IART - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday, Wall Street Zen reports.

A number of other research analysts have also recently issued reports on IART. UBS Group set a $14.00 price objective on Integra LifeSciences and gave the company a "neutral" rating in a research note on Tuesday. Citigroup reissued an "outperform" rating on shares of Integra LifeSciences in a report on Thursday, October 22nd. Weiss Ratings upgraded Integra LifeSciences from a "sell (e+)" rating to a "sell (d+)" rating in a report on Monday. Zacks Research downgraded Integra LifeSciences from a "hold" rating to a "strong sell" rating in a report on Monday, October 26th. Finally, Citizens Jmp lowered their price target on Integra LifeSciences from $25.00 to $22.00 and set a "market outperform" rating for the company in a research report on Thursday, October 22nd. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Reduce" and an average price target of $16.12.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $12.75 on Friday. The company has a current ratio of 3.62, a quick ratio of 2.11 and a debt-to-equity ratio of 1.67. The firm has a market capitalization of $991.96 million, a P/E ratio of 75.00, a P/E/G ratio of 0.50 and a beta of 1.21. The business has a fifty day simple moving average of $14.83 and a two-hundred day simple moving average of $14.08. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to analyst estimates of $413.16 million. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.63%. During the same period last year, the business earned ($0.07) EPS. On average, equities analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors have recently bought and sold shares of IART. State of Wyoming lifted its stake in shares of Integra LifeSciences by 40.7% during the 3rd quarter. State of Wyoming now owns 33,501 shares of the life sciences company's stock valued at $545,000 after buying an additional 9,691 shares in the last quarter. Access Investment Management LLC increased its stake in Integra LifeSciences by 39.5% in the 3rd quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company's stock worth $9,198,000 after buying an additional 159,980 shares in the last quarter. Inspire Investing LLC increased its stake in Integra LifeSciences by 5.2% in the 3rd quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company's stock worth $638,000 after buying an additional 1,929 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Integra LifeSciences by 221.7% during the second quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company's stock valued at $822,000 after acquiring an additional 31,552 shares during the period. Finally, WINTON GROUP Ltd bought a new stake in Integra LifeSciences during the second quarter valued at about $1,843,000. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra's neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.